

Xarelto's approval expanded

November 5 2012

(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

DVT occurs when a blood clot forms in a vein deep in the body. If a clot breaks away and travels to an artery in the lungs, it becomes a potentially deadly condition called a pulmonary embolism.

Xarelto was approved last year to treat clots stemming from knee or hip replacement and to lessen the risk of stroke in people with a form of [abnormal heart rhythm](#) called non-valvular atrial fibrillation.

The drug's newest approvals were given based on clinical studies involving 9,478 people, the FDA said in a news release. As with other anti-clotting drugs, bleeding is the most common side effect.

Xarelto is produced by Janssen Pharmaceuticals, based in Raritan, N.J.

More information: The FDA has more about [this approval](#).

Copyright © 2012 [HealthDay](#). All rights reserved.

Citation: Xarelto's approval expanded (2012, November 5) retrieved 19 April 2024 from <https://medicalxpress.com/news/2012-11-xarelto.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.